A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

810

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

DRUG: mezigdomide
DRUG: Pomalidomide
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

Celgene